Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AstraZeneca Q3 Adj. EPS $1.19 Beats $1.14 Estimate, Sales $15.191B Beat $14.805B Estimate

Author: Benzinga Newsdesk | November 06, 2025 03:21am
AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.14 by 4.39 percent. This is a 14.42 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $15.191 billion which beat the analyst consensus estimate of $14.805 billion by 2.61 percent. This is a 11.99 percent increase over sales of $13.565 billion the same period last year.

Posted In: AZN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist